-
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Tuesday, July 16, 2024 - 3:07pm | 943Read More...Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17....
-
Merck Q2 Earnings Preview: Analyst Expectations, Jim Cramer's View, And The Spotlight On Keytruda
Monday, July 31, 2023 - 12:34pm | 795Read More...Pharmaceutical company Merck & Company (NYSE: MRK) reports second quarter financial results before market open Tuesday. After being one of the 15 Dow Jones component stocks that traded higher in the first half of 2023, investors now see the stock down year-to-date. Here’s a look at the...
-
Investors Are Fleeing John Paulson's Once Hot Hedge Fund
Monday, June 5, 2017 - 9:51am | 431Read More...Hedge fund manager John Paulson accurately predicted the housing market collapse and positioned his investments accordingly. Years later, his once hot hedge fund is now anything but as investors are fleeing. Paulson has been on the losing side of several notable trades over the past few years,...
-
President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical'
Tuesday, January 31, 2017 - 11:57am | 491Read More...President Donald Trump said Tuesday that drug prices are "astronomical" and much needed change needs to be implemented. His comments come at a time when he hosted drug makers at the White House and are also consistent with promises he made both during and after the campaign trail....
-
Pfizer Fined $106 Million For Anti-Epilepsy Drug
Wednesday, December 7, 2016 - 8:56am | 326Read More...Shares of Pfizer Inc. (NYSE: PFE) were little changed after the company said it will appeal a $106 million fine by the United Kingdom's competition regulator, the Competition and Markets Authority (CMA). According to The Wall Street Journal, Pfizer was slapped with a £84.2 million...
-
Teva Pharmaceuticals Hit With A Slew Of Downgrades Following Guidance Revision
Wednesday, November 16, 2016 - 2:38pm | 698Read More...Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) hit a new 52-week low of $37.25 on Tuesday after the company reported its third-quarter results and provided a concerning outlook for the full year given some concerns over its specialty drugs. The stock rebounded slightly on Wednesday...
-
Bernie Sanders And Rep. Cummings To Ariad: Explain Why Iclusig Now Costs $199,000 A Year
Thursday, October 20, 2016 - 2:58pm | 532Read More...Sen. Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.) delivered a letter to Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) President and CEO Paris Panayiotopoulos. The purpose of the letter is to request information as to why the company felt justified in boosting the price of its Iclusig (...
-
Piper Jaffray Analyst: Latest Report On Valeant 'Doesn't Surprise Me'
Thursday, May 12, 2016 - 3:38pm | 293Read More...David Amsellem of Piper Jaffray was asked for his opinion on reports that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has yet to proceed with proposed price cuts for some of its drugs. Speaking as a guest on CNBC, Amsellem said the report "doesn't surprise me" for several reasons...
-
Valeant's Price Cut To Hospitals Just Lip Service?
Thursday, May 12, 2016 - 12:57pm | 380Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and its top management officials told a group of U.S. senators the company is open to slashing the price of some of its drugs. Valeant executives suggested a 30 percent discount on some of its drugs for hospitals. However, the cost for many life-...
-
Investment Fund Manager: GlaxoSmithKline Should Be Broken Up, Shares Tick Higher
Friday, January 8, 2016 - 12:57pm | 223Read More...Neil Woodford is the founder of Woodford Investment Management, an asset management company with £12.5bn of assets under management. Woodford is considered one of the Britain's most successful and influential investors and recently shared his thoughts of drug companies with the BBC. Woodford told...
-
Watson Pharmaceuticals Earnings Preview
Monday, July 25, 2011 - 11:13am | 647Read More...Watson Pharmaceuticals (NYSE: WPI) is scheduled to report its second-quarter 2011 results Tuesday, July 26, before the markets open. Strong first-quarter results pushed the share price to a new all-time high; can second-quarter results do the same? Analysts are looking for the drug maker to report...
